Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Merck TbkISX:MERK +0.53%84 EBITDA Margin % is 30.48% as of Mar. 2026, which is 56% above its 10-year median of 19.57. GuruFocus rates ISX:MERK with a GF Score™ of 84/100 and a GF Value™ of Rp4,944.61 (Modestly Undervalued). Among 961 Drug Manufacturers companies, PT Merck Tbk ranks better than 88.97% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. PT Merck Tbk's EBITDA for the
three
months ended in Mar. 2026 was Rp86,294 Mil. PT Merck Tbk's Revenue for the
three
months ended in Mar. 2026 was Rp283,105 Mil. Therefore, PT Merck Tbk's EBITDA margin for the quarter that ended in Mar. 2026 was 30.48%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
PT Merck Tbk EBITDA Margin % Related Terms
PT Merck Tbk EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for PT Merck Tbk's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:MERK vs ZTS, UTHR, VTRS: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PT Merck Tbk's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Merck Tbk EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Merck Tbk's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where PT Merck Tbk's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Merck Tbk (ISX:MERK) has a EBITDA Margin % of 30.48% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PT Merck Tbk and its competitors. This is 56% above median its historical median of 19.57. Over the past decade, PT Merck Tbk's EBITDA Margin % has ranged from 7.56 to 31.83. According to the industry distribution chart, PT Merck Tbk ranks #106 out of 961 companies in the Drug Manufacturers industry, placing it in the top 11%.
Is PT Merck Tbk's EBITDA Margin % too high?
PT Merck Tbk's current EBITDA Margin % of 30.48% is 56% above median its 10-year median of 19.57. Over the past 10 years, this metric has ranged from a low of 7.56 to a high of 31.83. The Drug Manufacturers industry median EBITDA Margin % is 12.49. PT Merck Tbk's value of 30.48% is 144% above this industry median. Based on the distribution chart, PT Merck Tbk ranks #106 out of 961 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, PT Merck Tbk has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PT Merck Tbk's EBITDA Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PT Merck Tbk ranks #106 out of 961 companies for EBITDA Margin %. This places PT Merck Tbk in the top 11% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.49. PT Merck Tbk's value of 30.48% is 144% above this benchmark. Historically, PT Merck Tbk's own EBITDA Margin % has ranged from 7.56 to 31.83 over the past decade. While the company's 10-year median is 19.57 vs. the industry median of 12.49, PT Merck Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.49, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Merck Tbk's current EBITDA Margin % of 30.48% is 144% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PT Merck Tbk and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Merck Tbk's current EBITDA Margin % is 30.48%, which is 56% above median its own 10-year median of 19.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Merck Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Merck Tbk (ISX:MERK) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp4,944.61, compared to a current price of Rp3,760.00 — trading 24% below its estimated fair value. The current EBITDA Margin % is 30.48%, which is 56% above median its 10-year median of 19.57 and 144% above the Drug Manufacturers industry median of 12.49. PT Merck Tbk's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PT Merck Tbk (ISX:MERK), the current EBITDA Margin % is 30.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Merck Tbk (ISX:MERK) Overvalued in 2026?
Based on GuruFocus' analysis, PT Merck Tbk stock appears to be undervalued.
The current stock price of Rp3,760.00 is trading 24% below its estimated GF Value™ of Rp4,944.61.
GuruFocus considers PT Merck Tbk to be Modestly Undervalued.
Key valuation signals for ISX:MERK:
EBITDA Margin %: 30.48% (56% above median its 10-year median of 19.57)
GF Value™: Rp4,944.61 vs. price of Rp3,760.00 (24% below fair value)
Industry Position: 144% above the Drug Manufacturers median (#106 of 961)
No single metric tells the full story. See the ISX:MERK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Merck Tbk engages in the manufacture and sale of pharmaceutical products in Indonesia. The company operates in three segments: Biopharma, Consumer Health, and Others. The company offers pharmaceutical and biological prescription medicines for colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, as well as thyroid disorders such as hypothyroidism.
84GF Score
Get the complete analysis for ISX:MERK
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:MERK has been successfully added to your 
